RxDoctor Payments Data
★ My doctorsLook up a doctor →

William Goldman

Psychiatry · Southlake, TXNPI 1962538488

Payments from drug & device makers

$5,745in general payments, 2019–2025

Across 268 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$603
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$590
  • Merz North America, Inc.$535
  • Bausch Health US, LLC$472
  • Johnson & Johnson$468
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$5,745100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)63$1,090
Takeda Pharmaceuticals U.S.A., Inc.32$603
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)27$590
Merz North America, Inc.3$535
Bausch Health US, LLC38$472
Johnson & Johnson15$468
Tris Pharma Inc10$340
Lundbeck LLC17$289
Otsuka America Pharmaceutical, Inc.13$249
Vanda Pharmaceuticals Inc.13$232
Ironshore Pharmaceuticals Inc.11$214
Supernus Pharmaceuticals, Inc.5$202
Galderma Laboratories, L.p.1$100
Adlon Therapeutics L.p.6$97
Corium, LLC3$71
Neurocrine Biosciences, Inc.4$65
Alkermes, Inc.2$41
Shire North American Group Inc2$30
Axsome Therapeutics, Inc.1$28
Neos Therapeutics, LP1$16
Bausch & Lomb, A Division Of Bausch Health US, LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,745 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas →

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl12$34,677
TrintellixVortioxetine Hydrobromide11$5,301
Aripiprazole18$1,484
Bupropion XlBupropion Hcl23$973
Duloxetine Hcl22$788
Ziprasidone Hcl15$741
Olanzapine25$593
Venlafaxine Hcl ErVenlafaxine Hcl25$586
Desvenlafaxine Succinate ErDesvenlafaxine Succinate17$366
Gabapentin18$301
Mirtazapine13$281
Trazodone Hcl19$265
Escitalopram Oxalate25$215
Clonazepam27$185
Zolpidem Tartrate11$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$603$5,30111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Southlake

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →